GeoVax Labs (NASDAQ:GOVX) vs. InMed Pharmaceuticals (NASDAQ:INM) Head to Head Analysis

InMed Pharmaceuticals (NASDAQ:INM) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Institutional & Insider Ownership

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of GeoVax Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

InMed Pharmaceuticals has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500.

Valuation and Earnings

This table compares InMed Pharmaceuticals and GeoVax Labs”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.60 million	0.56	-$7.68 million	($1.32)	-0.22
GeoVax Labs	$300,677.00	17.89	-$25.97 million	N/A	N/A

InMed Pharmaceuticals has higher revenue and earnings than GeoVax Labs.

Profitability

This table compares InMed Pharmaceuticals and GeoVax Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-166.94%	-71.97%	-59.79%
GeoVax Labs	N/A	-852.60%	-326.87%

Analyst Recommendations

This is a summary of current recommendations and price targets for InMed Pharmaceuticals and GeoVax Labs, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	0	0	0	0	N/A
GeoVax Labs	0	0	3	2	3.40

GeoVax Labs has a consensus price target of $12.67, indicating a potential upside of 439.01%. Given GeoVax Labs’ higher probable upside, analysts plainly believe GeoVax Labs is more favorable than InMed Pharmaceuticals.

Summary

GeoVax Labs beats InMed Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

About GeoVax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.